Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and predictors of clinical failure after early treatment for mild-to-moderate COVID-19 in high-risk individuals: A multicentric cohort study.
Mastrorosa I, Lepri AC, Borgo CD, Rosati S, Rueca M, Sarmati L, Mastroianni C, Fantoni M, Maggi F, Nicastri E, Girardi E, Lichtner M, Antinori A, Mazzotta V; Early Treatment for COVID‐19 Lazio Study Group. Mastrorosa I, et al. Among authors: mazzotta v. J Intern Med. 2024 Nov 13. doi: 10.1111/joim.20030. Online ahead of print. J Intern Med. 2024. PMID: 39537383
MPXV infection impairs IFN response but is partially sensitive to IFN-γ antiviral effect.
Bordi L, D'Auria A, Frasca F, Mazzotta V, Mazzetti P, Fracella M, d'Ettorre G, Antonelli G, Pistello M, Antinori A, Viscidi RP, Maggi F, Lalle E, Scagnolari C. Bordi L, et al. Among authors: mazzotta v. Med Microbiol Immunol. 2024 Nov 11;213(1):25. doi: 10.1007/s00430-024-00808-w. Med Microbiol Immunol. 2024. PMID: 39527317
Cognitive outcomes and psychological symptoms in an Italian cohort with post-acute COVID-19 condition (PACC).
Vergori A, Del Duca G, Borrelli P, Brita AC, Pinnetti C, Mastrorosa I, Camici M, Mondi A, Mazzotta V, Chinello P, Mencarini P, Giancola ML, Abdeddaim A, Girardi E, Antinori A. Vergori A, et al. Among authors: mazzotta v. Heliyon. 2024 Oct 16;10(20):e39431. doi: 10.1016/j.heliyon.2024.e39431. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39469684 Free PMC article.
Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition.
Vergori A, Del Duca G, Lorenzini P, Brita AC, Mastrorosa I, Fusto M, Camici M, Ottou S, Gagliardini R, Paulicelli J, De Zottis F, Grilli E, Esvan R, Plazzi MM, Mazzotta V, Bellagamba R, Antinori A, Pinnetti C. Vergori A, et al. Among authors: mazzotta v. AIDS. 2024 Oct 25. doi: 10.1097/QAD.0000000000004043. Online ahead of print. AIDS. 2024. PMID: 39453875
Mpox Immune response elicited by MVA-BN vaccine over 12 months of follow-up.
Matusali G, Cimini E, Mazzotta V, Colavita F, Maggi F, Antinori A. Matusali G, et al. Among authors: mazzotta v. J Infect. 2024 Oct 4;89(6):106309. doi: 10.1016/j.jinf.2024.106309. Online ahead of print. J Infect. 2024. PMID: 39368640 Free article. No abstract available.
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
Mazzotta V, Mazzaferri F, Lanini S, Mirandola M, Cozzi Lepri A, Vergori A, Savoldi A, Santoro A, Maccarrone G, Mastrorosa I, Simonetti O, Zottis F, Nicastri E, Rosini G, Rovigo L, Tavernaro L, Sarmati L, Tascini C, Girardi E, Cattelan AM, Antinori A, Tacconelli E; MANTICO2/MONET study group. Mazzotta V, et al. J Infect. 2024 Nov;89(5):106294. doi: 10.1016/j.jinf.2024.106294. Epub 2024 Sep 27. J Infect. 2024. PMID: 39343244 Free article. Clinical Trial.
Impact of Anti-SARS-CoV-2 Vaccination on Disease Severity and Clinical Outcomes of Individuals Hospitalized for COVID-19 Throughout Successive Pandemic Waves: Data from an Italian Reference Hospital.
Mondi A, Mastrorosa I, Navarra A, Cimaglia C, Pinnetti C, Mazzotta V, Agresta A, Corpolongo A, Zolezzi A, Al Moghazi S, Loiacono L, Bocci MG, Matusali G, D'Annunzio A, Gallì P, Maggi F, Vairo F, Girardi E, Antinori A. Mondi A, et al. Among authors: mazzotta v. Vaccines (Basel). 2024 Sep 6;12(9):1018. doi: 10.3390/vaccines12091018. Vaccines (Basel). 2024. PMID: 39340048 Free PMC article.
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona).
Mazzotta V, Nozza S, Lanini S, Moschese D, Tavelli A, Rossotti R, Fusco FM, Biasioli L, Matusali G, Raccagni AR, Mileto D, Maci C, Lapadula G, Di Biagio A, Pipitò L, Tamburrini E, Monforte AD, Castagna A, Antinori A; mpox-Icona study group. Mazzotta V, et al. EBioMedicine. 2024 Sep;107:105289. doi: 10.1016/j.ebiom.2024.105289. Epub 2024 Aug 22. EBioMedicine. 2024. PMID: 39178746 Free PMC article.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study group. Cingolani A, et al. J Antimicrob Chemother. 2024 Oct 1;79(10):2662-2667. doi: 10.1093/jac/dkae273. J Antimicrob Chemother. 2024. PMID: 39140512
Role of Direct Sexual Contact in Human Transmission of Monkeypox Virus, Italy.
Sberna G, Rozera G, Minosse C, Bordi L, Mazzotta V, D'Abramo A, Girardi E, Antinori A, Maggi F, Lalle E. Sberna G, et al. Among authors: mazzotta v. Emerg Infect Dis. 2024 Sep;30(9):1829-1833. doi: 10.3201/eid3009.240075. Epub 2024 Aug 10. Emerg Infect Dis. 2024. PMID: 39127126 Free PMC article.
95 results